Press Releases

Date Title and Summary    
Toggle Summary Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117
Patent Protection for RX-3117 Extended until 2036
View HTML Print
Toggle Summary Rexahn Announces $10 Million Registered Direct Offering
ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 3.03 million shares of its common stock and warrants exercisable for up to approximately
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Metastatic Bladder Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments Stage 2 of the Study has Begun, Based on Positive Preliminary Efficacy Results from Stage 1
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
ROCKVILLE, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it will present preliminary data from the Phase IIa study of
View HTML Print
Toggle Summary Rexahn Effects 1-for-10 Reverse Stock Split
ROCKVILLE, Md., May 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) ("Rexahn" or the "Company"), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that the Company's previously announced
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
Completed Phase I dose-escalation study with Supinoxin™ in solid tumors Initiated Phase IIa clinical trial of Supinoxin in Metastatic Triple Negative Breast Cancer ROCKVILLE, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical
View HTML Print
Toggle Summary Rexahn Announces 1-for-10 Reverse Stock Split
ROCKVILLE, Md., April 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it will implement a 1-for-10 reverse stock split of outstanding
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update
Progressed Three Novel Targeted Anti-Cancer Therapies in Clinical Development Completed stage 1 and initiated stage 2 of Phase IIa clinical trial of RX-3117 in Relapsed and Refractory Metastatic Pancreatic Cancer Initiated Phase IIa clinical trial of Archexin ® in Metastatic Renal Cell Carcinoma
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer
ROCKVILLE, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), today announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin™ in metastatic triple negative breast cancer (TNBC).  The study will evaluate the safety and efficacy of
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
Evidence of Prolonged Progression Free Survival in Pancreatic Cancer Patients Treated with RX-3117 and for Whom Three or More Prior Therapies had been Ineffective
View HTML Print


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy